;PMID: 2604739
;source_file_1891.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..46] = [t:0..46]
;1)sentence:[e:52..114] = [t:52..114]
;2)sentence:[e:115..198] = [t:115..198]
;3)section:[e:202..221] = [t:202..221]
;4)section:[e:225..305] = [t:225..305]
;5)sentence:[e:309..404] = [t:309..404]
;6)sentence:[e:405..552] = [t:405..552]
;7)sentence:[e:553..705] = [t:553..705]
;8)sentence:[e:707..891] = [t:707..891]
;9)sentence:[e:892..1115] = [t:892..1115]
;10)sentence:[e:1116..1313] = [t:1116..1313]
;11)sentence:[e:1314..1447] = [t:1314..1447]
;12)sentence:[e:1448..1613] = [t:1448..1613]
;13)sentence:[e:1614..1806] = [t:1614..1806]
;14)sentence:[e:1807..1930] = [t:1807..1930]
;15)sentence:[e:1931..2099] = [t:1931..2099]
;16)sentence:[e:2100..2262] = [t:2100..2262]
;17)section:[e:2266..2310] = [t:2266..2310]

;section 0 Span:0..46
;Biochem Pharmacol. 1989 Dec 15;38(24):4359-65.
(SEC
  (FRAG (NNP:[0..7] Biochem) (NNP:[8..17] Pharmacol) (,:[17..18] .)
        (CD:[19..23] 1989) (NNP:[24..27] Dec) (CC:[28..34] 15;38-LRB-)
        (CD:[34..36] 24) (-RRB-:[36..37] -RRB-) (CD:[37..41] :435)
        (CD:[41..42] 9) (NN:[42..43] -) (CD:[43..45] 65) (.:[45..46] .)))

;sentence 1 Span:52..114
;In vitro inhibition of hepatic drug oxidation by thioridazine.
;[83..87]:substance:"drug"
;[101..113]:substance:"thioridazine"
(SENT
  (NP-HLN
    (NP
      (ADJP (FW:[52..54] In) (FW:[55..60] vitro))
      (NN:[61..71] inhibition))
    (PP (IN:[72..74] of)
      (NP (JJ:[75..82] hepatic) (NN:[83..87] drug) (NN:[88..97] oxidation)))
    (PP (IN:[98..100] by)
      (NP (NN:[101..113] thioridazine)))
    (.:[113..114] .)))

;sentence 2 Span:115..198
;Kinetic analysis  of the inhibition of cytochrome P-450 isoform-specific
;reactions.
;[154..178]:cyp450:"cytochrome P-450 isoform"
(SENT
  (NP-HLN
    (NP (JJ:[115..122] Kinetic) (NN:[123..131] analysis))
    (PP (IN:[133..135] of)
      (NP
        (NP (DT:[136..139] the) (NN:[140..150] inhibition))
        (PP (IN:[151..153] of)
          (NP
            (ADJP
              (NML
                (NML (NN:[154..164] cytochrome) (NN:[165..170] P-450))
                (NN:[171..178] isoform))
              (HYPH:[178..179] -) (JJ:[179..187] specific))
            (NNS:[188..197] reactions)))))
    (.:[197..198] .)))

;section 3 Span:202..221
;Murray M, Reidy GF.
(SEC
  (FRAG (NNP:[202..208] Murray) (NNP:[209..211] M,) (NNP:[212..217] Reidy)
        (NNP:[218..221] GF.)))

;section 4 Span:225..305
;Department of Medicine, University of Sydney, Westmead Hospital, NSW,
;Australia.
(SEC
  (FRAG (NNP:[225..235] Department) (IN:[236..238] of) (NNP:[239..247] Medicine)
        (,:[247..248] ,) (NNP:[249..259] University) (IN:[260..262] of)
        (NNP:[263..269] Sydney) (,:[269..270] ,) (NNP:[271..279] Westmead)
        (NNP:[280..288] Hospital) (,:[288..289] ,) (NNP:[290..293] NSW)
        (,:[293..294] ,) (NNP:[295..304] Australia) (.:[304..305] .)))

;sentence 5 Span:309..404
;The phenothiazine tranquilizer thioridazine has been associated with drug 
;interactions in man.
;[313..339]:substance:"phenothiazine tranquilizer"
;[340..352]:substance:"thioridazine"
;[378..382]:substance:"drug"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[309..312] The)
         (NN:[313..326] phenothiazine) (NN:[327..339] tranquilizer))
      (NP (NN:[340..352] thioridazine)))
    (VP (VBZ:[353..356] has)
      (VP (VBN:[357..361] been)
        (VP (VBN:[362..372] associated)
          (NP-1 (-NONE-:[372..372] *))
          (PP-CLR (IN:[373..377] with)
            (NP (NN:[378..382] drug) (NNS:[384..396] interactions)))
          (PP-LOC (IN:[397..399] in)
            (NP (NN:[400..403] man))))))
    (.:[403..404] .)))

;sentence 6 Span:405..552
;This study investigated the capacity of the drug to inhibit  hepatic drug
;oxidations mediated by cytochromes P-450 (P-450) in microsomes in  vitro.
;[449..453]:substance:"drug"
;[474..478]:substance:"drug"
;[502..519]:cyp450:"cytochromes P-450"
;[521..526]:cyp450:"P-450"
(SENT
  (S
    (NP-SBJ (DT:[405..409] This) (NN:[410..415] study))
    (VP (VBD:[416..428] investigated)
      (NP
        (NP (DT:[429..432] the) (NN:[433..441] capacity)
          (S-1 (-NONE-:[441..441] *ICH*)))
        (PP (IN:[442..444] of)
          (NP (DT:[445..448] the) (NN:[449..453] drug)))
        (S-1
          (NP-SBJ (-NONE-:[453..453] *))
          (VP (TO:[454..456] to)
            (VP (VB:[457..464] inhibit)
              (NP
                (NP (JJ:[466..473] hepatic) (NN:[474..478] drug)
                    (NNS:[479..489] oxidations))
                (VP (VBN:[490..498] mediated)
                  (NP (-NONE-:[498..498] *))
                  (PP-MNR (IN:[499..501] by)
                    (NP
                      (NP
                        (NP (NNS:[502..513] cytochromes) (NN:[514..519] P-450))
                        (NP (-LRB-:[520..521] -LRB-) (NN:[521..526] P-450)
                            (-RRB-:[526..527] -RRB-)))
                      (PP-LOC (IN:[528..530] in)
                        (NP (NNS:[531..541] microsomes)))))
                  (ADVP (FW:[542..544] in) (FW:[546..551] vitro)))))))))
    (.:[551..552] .)))

;sentence 7 Span:553..705
;Thioridazine was a potent linear mixed-type inhibitor of P-450b-dependent 
;7-pentoxyresorufin O-depentylase activity in phenobarbital-induced rat
;liver.
;[553..565]:substance:"Thioridazine"
;[597..606]:substance:"inhibitor"
;[610..616]:cyp450:"P-450b"
;[628..660]:substance:"7-pentoxyresorufin O-depentylase"
;[673..686]:substance:"phenobarbital"
(SENT
  (S
    (NP-SBJ (NN:[553..565] Thioridazine))
    (VP (VBD:[566..569] was)
      (NP-PRD
        (NP (DT:[570..571] a) (JJ:[572..578] potent) (JJ:[579..585] linear)
          (NML (VBN:[586..591] mixed) (HYPH:[591..592] -) (NN:[592..596] type))
          (NN:[597..606] inhibitor))
        (PP (IN:[607..609] of)
          (NP
            (ADJP (NN:[610..616] P-450b) (HYPH:[616..617] -)
                  (JJ:[617..626] dependent))
             (NN:[628..646] 7-pentoxyresorufin) (NN:[647..660] O-depentylase)
            (NN:[661..669] activity))))
      (PP-LOC (IN:[670..672] in)
        (NP
          (ADJP (NN:[673..686] phenobarbital) (HYPH:[686..687] -)
                (VBN:[687..694] induced))
          (NN:[695..698] rat) (NN:[699..704] liver))))
    (.:[704..705] .)))

;sentence 8 Span:707..891
;The kinetic analysis revealed the enzyme-substrate dissociation constant (Ks)
;to  be 1.6 microM whereas the dissociation constant of the enzyme-inhibitor
;complex  (Ki) was 0.11 microM.
;[741..747]:substance:"enzyme"
;[748..757]:substance:"substrate"
;[781..783]:quantitative-name:"Ks"
;[792..795]:quantitative-value:"1.6"
;[796..802]:quantitative-units:"microM"
;[844..868]:substance:"enzyme-inhibitor complex"
;[871..873]:quantitative-name:"Ki"
;[879..883]:quantitative-value:"0.11"
;[884..890]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (DT:[707..710] The) (JJ:[711..718] kinetic) (NN:[719..727] analysis))
    (VP (VBD:[728..736] revealed)
      (S
        (NP-SBJ (DT:[737..740] the)
          (NML (NN:[741..747] enzyme) (HYPH:[747..748] -)
               (NN:[748..757] substrate))
          (NN:[758..770] dissociation) (NN:[771..779] constant)
          (PRN (-LRB-:[780..781] -LRB-)
            (NP (NN:[781..783] Ks))
            (-RRB-:[783..784] -RRB-)))
        (VP (TO:[785..787] to)
          (VP (VB:[789..791] be)
            (NP-PRD (CD:[792..795] 1.6) (NN:[796..802] microM)))))
      (SBAR-ADV (IN:[803..810] whereas)
        (S
          (NP-SBJ
            (NP (DT:[811..814] the) (NN:[815..827] dissociation)
                (NN:[828..836] constant))
            (PP (IN:[837..839] of)
              (NP (DT:[840..843] the)
                
                (NML (NN:[844..850] enzyme) (HYPH:[850..851] -)
                     (NN:[851..860] inhibitor))
                (NN:[861..868] complex)))
            (PRN (-LRB-:[870..871] -LRB-)
              (NP (NN:[871..873] Ki))
              (-RRB-:[873..874] -RRB-)))
          (VP (VBD:[875..878] was)
            (NP-PRD (CD:[879..883] 0.11) (NN:[884..890] microM))))))
    (.:[890..891] .)))

;sentence 9 Span:892..1115
;In contrast, 7-ethoxyresorufin O-deethylase activity  (mediated by P-450c) in
;beta-naphthoflavone-induced rat hepatic microsomes was  inhibited to a lesser
;extent (Ki = 2.4 microM) in relation to the Ks value (0.5  microM).
;[905..935]:substance:"7-ethoxyresorufin O-deethylase"
;[959..965]:cyp450:"P-450c"
;[970..989]:substance:"beta-naphthoflavone"
;[1056..1058]:quantitative-name:"Ki"
;[1061..1064]:quantitative-value:"2.4"
;[1065..1071]:quantitative-units:"microM"
;[1092..1094]:quantitative-name:"Ks"
;[1102..1105]:quantitative-value:"0.5"
;[1107..1113]:quantitative-units:"microM"
(SENT
  (S
    (PP (IN:[892..894] In)
      (NP (NN:[895..903] contrast)))
    (,:[903..904] ,)
    (NP-SBJ
      (NP
         (NN:[905..922] 7-ethoxyresorufin) (NN:[923..935] O-deethylase)
        (NN:[936..944] activity))
      (PRN (-LRB-:[946..947] -LRB-)
        (VP (VBN:[947..955] mediated)
          (NP (-NONE-:[955..955] *))
          (PP (IN:[956..958] by)
            (NP-LGS (NN:[959..965] P-450c))))
        (-RRB-:[965..966] -RRB-))
      (PP-LOC (IN:[967..969] in)
        (NP
          (ADJP (NN:[970..989] beta-naphthoflavone) (HYPH:[989..990] -)
                (VBN:[990..997] induced))
          (NN:[998..1001] rat) (JJ:[1002..1009] hepatic)
           (NNS:[1010..1020] microsomes))))
    (VP (VBD:[1021..1024] was)
      (VP (VBN:[1026..1035] inhibited)
        (PP-EXT (TO:[1036..1038] to)
          (NP (DT:[1039..1040] a) (JJR:[1041..1047] lesser)
              (NN:[1048..1054] extent)
            (PRN (-LRB-:[1055..1056] -LRB-)
              (S
                (NP-SBJ (NN:[1056..1058] Ki))
                (VP (SYM:[1059..1060] =)
                  (NP (CD:[1061..1064] 2.4) (NN:[1065..1071] microM))))
              (-RRB-:[1071..1072] -RRB-))))
        (PP (IN:[1073..1075] in)
          (NP
            (NP (NN:[1076..1084] relation))
            (PP (TO:[1085..1087] to)
              (NP (DT:[1088..1091] the) (NN:[1092..1094] Ks)
                  (NN:[1095..1100] value)
                (PRN (-LRB-:[1101..1102] -LRB-)
                  (NP (CD:[1102..1105] 0.5) (NN:[1107..1113] microM))
                  (-RRB-:[1113..1114] -RRB-))))))))
    (.:[1114..1115] .)))

;sentence 10 Span:1116..1313
;Spectral studies indicated that the efficiency of thioridazine binding  in
;phenobarbital-induced microsomes was about 25-fold greater than in microsomes
; from beta-naphthoflavone-induced rat liver.
;[1166..1178]:substance:"thioridazine"
;[1191..1204]:substance:"phenobarbital"
;[1234..1254]:quantitative-value:"25-fold greater than"
;[1275..1294]:substance:"beta-naphthoflavone"
(SENT
  (S
    (NP-SBJ (JJ:[1116..1124] Spectral) (NNS:[1125..1132] studies))
    (VP (VBD:[1133..1142] indicated)
      (SBAR (IN:[1143..1147] that)
        (S
          (NP-SBJ
            (NP (DT:[1148..1151] the) (NN:[1152..1162] efficiency))
            (PP (IN:[1163..1165] of)
              (NP (NN:[1166..1178] thioridazine) (NN:[1179..1186] binding)))
            (PP-LOC (IN:[1188..1190] in)
              (NP
                (ADJP (NN:[1191..1204] phenobarbital) (HYPH:[1204..1205] -)
                      (VBN:[1205..1212] induced))
                (NNS:[1213..1223] microsomes))))
          (VP (VBD:[1224..1227] was)
            (ADJP-PRD
              (ADJP
                (ADVP
                  (QP (RB:[1228..1233] about) (CD:[1234..1236] 25)
                      (HYPH:[1236..1237] -) (RB:[1237..1241] fold)))
                (JJR:[1242..1249] greater))
              (PP (IN:[1250..1254] than)
                (PP-LOC (IN:[1255..1257] in)
                  (NP
                    (NP (NNS:[1258..1268] microsomes))
                    (PP (IN:[1270..1274] from)
                      (NP
                        (ADJP (NN:[1275..1294] beta-naphthoflavone)
                              (HYPH:[1294..1295] -) (VBN:[1295..1302] induced))
                        (NN:[1303..1306] rat) (NN:[1307..1312] liver)))))))))))
    (.:[1312..1313] .)))

;sentence 11 Span:1314..1447
;This finding is consistent with the  relative capacity of thioridazine to
;inhibit oxidase activities catalyzed by  P-450b and P-450c.
;[1372..1384]:substance:"thioridazine"
;[1396..1403]:substance:"oxidase"
;[1429..1435]:cyp450:"P-450b"
;[1440..1446]:cyp450:"P-450c"
(SENT
  (S
    (NP-SBJ (DT:[1314..1318] This) (NN:[1319..1326] finding))
    (VP (VBZ:[1327..1329] is)
      (ADJP-PRD (JJ:[1330..1340] consistent)
        (PP (IN:[1341..1345] with)
          (NP
            (NP (DT:[1346..1349] the) (JJ:[1351..1359] relative)
                (NN:[1360..1368] capacity)
              (S-1 (-NONE-:[1368..1368] *ICH*)))
            (PP (IN:[1369..1371] of)
              (NP (NN:[1372..1384] thioridazine)))
            (S-1
              (NP-SBJ (-NONE-:[1384..1384] *))
              (VP (TO:[1385..1387] to)
                (VP (VB:[1388..1395] inhibit)
                  (NP
                    (NP (NN:[1396..1403] oxidase) (NNS:[1404..1414] activities))
                    (VP (VBN:[1415..1424] catalyzed)
                      (NP (-NONE-:[1424..1424] *))
                      (PP (IN:[1425..1427] by)
                        (NP-LGS (NN:[1429..1435] P-450b) (CC:[1436..1439] and)
                                (NN:[1440..1446] P-450c))))))))))))
    (.:[1446..1447] .)))

;sentence 12 Span:1448..1613
;Mixed-function oxidase activities catalysed by other P-450s  were also
;inhibited by thioridazine, although to a lesser extent than those  catalysed
;by forms b and c.
;[1463..1470]:substance:"oxidase"
;[1501..1507]:cyp450:"P-450s"
;[1532..1544]:substance:"thioridazine"
;[1599..1606]:cyp450:"forms b"
;[1599..1604]...[1611..1612]:cyp450:"forms"..."c"
(SENT
  (S
    (NP-SBJ
      (NP
        (NML (VBN:[1448..1453] Mixed) (HYPH:[1453..1454] -)
             (NN:[1454..1462] function))
        (NN:[1463..1470] oxidase) (NNS:[1471..1481] activities))
      (VP (VBN:[1482..1491] catalysed)
        (NP (-NONE-:[1491..1491] *))
        (PP (IN:[1492..1494] by)
          (NP-LGS (JJ:[1495..1500] other) (NNS:[1501..1507] P-450s)))))
    (VP (VBD:[1509..1513] were)
      (ADVP (RB:[1514..1518] also))
      (VP (VBN:[1519..1528] inhibited)
        (PP (IN:[1529..1531] by)
          (NP-LGS (NN:[1532..1544] thioridazine)))
        (,:[1544..1545] ,)
        (PP (IN:[1546..1554] although)
          (PP (TO:[1555..1557] to)
            (NP
              (NP (DT:[1558..1559] a) (JJR:[1560..1566] lesser)
                  (NN:[1567..1573] extent))
              (PP (IN:[1574..1578] than)
                (NP
                  (NP (DT:[1579..1584] those))
                  (VP (VBN:[1586..1595] catalysed)
                    (NP (-NONE-:[1595..1595] *))
                    (PP (IN:[1596..1598] by)
                      (NP-LGS
                        (NP
                          (NML-1 (NNS:[1599..1604] forms))
                          (NN:[1605..1606] b))
                        (CC:[1607..1610] and)
                        (NP
                          (NML-1 (-NONE-:[1610..1610] *P*))
                          (NN:[1611..1612] c))))))))))))
    (.:[1612..1613] .)))

;sentence 13 Span:1614..1806
;Thus, the 6 beta- and 16 beta-hydroxylations of  androst-4-ene-3,17-dione in
;hepatic microsomes from untreated rats were  inhibited to a similar extent
;(I50S = 52 and 43 microM, respectively).
;[1663..1687]:substance:"androst-4-ene-3,17-dione"
;[1767..1771]:quantitative-name:"I50S"
;[1774..1776]:quantitative-value:"52"
;[1781..1783]:quantitative-value:"43"
;[1784..1790]:quantitative-units:"microM"
(SENT
  (S
    (ADVP (RB:[1614..1618] Thus))
    (,:[1618..1619] ,)
    (NP-SBJ-3
      (NP (DT:[1620..1623] the)
        (NML
          (NML
            (NML (CD:[1624..1625] 6) (SYM:[1626..1630] beta))
            (HYPH:[1630..1631] -)
            (NML-2 (-NONE-:[1631..1631] *P*)))
          (CC:[1632..1635] and)
          (NML
            (NML (CD:[1636..1638] 16) (SYM:[1639..1643] beta))
            (HYPH:[1643..1644] -)
            (NML-2 (NNS:[1644..1658] hydroxylations)))))
      (PP (IN:[1659..1661] of)
        (NP (NN:[1663..1687] androst-4-ene-3,17-dione)))
      (PP-LOC (IN:[1688..1690] in)
        (NP
          (NP (JJ:[1691..1698] hepatic) (NNS:[1699..1709] microsomes))
          (PP (IN:[1710..1714] from)
            (NP (JJ:[1715..1724] untreated) (NNS:[1725..1729] rats))))))
    (VP (VBD:[1730..1734] were)
      (VP (VBN:[1736..1745] inhibited)
        (NP-3 (-NONE-:[1745..1745] *))
        (PP (TO:[1746..1748] to)
          (NP (DT:[1749..1750] a) (JJ:[1751..1758] similar)
              (NN:[1759..1765] extent)))
        (PRN (-LRB-:[1766..1767] -LRB-)
          (S
            (NP-SBJ (NN:[1767..1771] I50S))
            (VP (SYM:[1772..1773] =)
              (NP
                (NP (CD:[1774..1776] 52)
                  (NML-1 (-NONE-:[1776..1776] *P*)))
                (CC:[1777..1780] and)
                (NP (CD:[1781..1783] 43)
                  (NML-1 (NN:[1784..1790] microM))))
              (,:[1790..1791] ,)
              (ADVP (RB:[1792..1804] respectively))))
          (-RRB-:[1804..1805] -RRB-))))
    (.:[1805..1806] .)))

;sentence 14 Span:1807..1930
;The 7  alpha- and 16 alpha-hydroxylase pathways were approximately only half
;as  susceptible to inhibition by thioridazine.
;[1811..1820]...[1834..1845]:substance:"7  alpha-"..."hydroxylase"
;[1825..1845]:substance:"16 alpha-hydroxylase"
;[1917..1929]:substance:"thioridazine"
(SENT
  (S
    (NP-SBJ (DT:[1807..1810] The)
      (NML
        (NML
          (NML
            (NML (CD:[1811..1812] 7) (SYM:[1814..1819] alpha))
            (HYPH:[1819..1820] -)
            (NML-1 (-NONE-:[1820..1820] *P*)))
          (NML-2 (-NONE-:[1820..1820] *P*)))
        (CC:[1821..1824] and)
        (NML
          (NML
            (NML (CD:[1825..1827] 16) (SYM:[1828..1833] alpha))
            (HYPH:[1833..1834] -)
            (NML-1 (NN:[1834..1845] hydroxylase)))
          (NML-2 (NNS:[1846..1854] pathways)))))
    (VP (VBD:[1855..1859] were)
      (ADJP-PRD
        (QP (RB:[1860..1873] approximately) (RB:[1874..1878] only)
            (RB:[1879..1883] half) (RB:[1884..1886] as))
        (JJ:[1888..1899] susceptible)
        (PP (TO:[1900..1902] to)
          (NP
            (NP (NN:[1903..1913] inhibition))
            (PP (IN:[1914..1916] by)
              (NP (NN:[1917..1929] thioridazine)))))))
    (.:[1929..1930] .)))

;sentence 15 Span:1931..2099
;These findings demonstrate the  capacity of thioridazine to inhibit a range
;of P-450-dependent drug oxidations,  with those catalysed by forms b and c
;most susceptible.
;[1975..1987]:substance:"thioridazine"
;[2010..2015]:cyp450:"P-450"
;[2026..2030]:substance:"drug"
;[2068..2075]:cyp450:"forms b"
;[2068..2073]...[2080..2081]:cyp450:"forms"..."c"
(SENT
  (S
    (NP-SBJ (DT:[1931..1936] These) (NNS:[1937..1945] findings))
    (VP (VBP:[1946..1957] demonstrate)
      (NP
        (NP (DT:[1958..1961] the) (NN:[1963..1971] capacity))
        (PP (IN:[1972..1974] of)
          (NP (NN:[1975..1987] thioridazine)))
        (S-ADV
          (NP-SBJ (-NONE-:[1987..1987] *))
          (VP (TO:[1988..1990] to)
            (VP (VB:[1991..1998] inhibit)
              (NP
                (NP (DT:[1999..2000] a) (NN:[2001..2006] range))
                (PP (IN:[2007..2009] of)
                  (NP
                    (ADJP (NN:[2010..2015] P-450) (HYPH:[2015..2016] -)
                          (JJ:[2016..2025] dependent))
                    (NN:[2026..2030] drug) (NNS:[2031..2041] oxidations))))
              (,:[2041..2042] ,)
              (PP (IN:[2044..2048] with)
                (S-NOM
                  (NP-SBJ
                    (NP (DT:[2049..2054] those))
                    (VP (VBN:[2055..2064] catalysed)
                      (NP (-NONE-:[2064..2064] *))
                      (PP (IN:[2065..2067] by)
                        (NP-LGS
                          (NP
                            (NML-1 (NNS:[2068..2073] forms))
                            (NN:[2074..2075] b))
                          (CC:[2076..2079] and)
                          (NP
                            (NML-1 (-NONE-:[2079..2079] *P*))
                            (NN:[2080..2081] c))))))
                  (ADJP-PRD (RBS:[2082..2086] most)
                            (JJ:[2087..2098] susceptible)))))))))
    (.:[2098..2099] .)))

;sentence 16 Span:2100..2262
;The present study  strongly suggests that drug interactions elicited by
;thioridazine are most  likely a consequence of inhibitory interactions with
;P-450 enzymes.
;[2142..2146]:substance:"drug"
;[2172..2184]:substance:"thioridazine"
;[2248..2261]:cyp450:"P-450 enzymes"
(SENT
  (S
    (NP-SBJ (DT:[2100..2103] The) (JJ:[2104..2111] present)
            (NN:[2112..2117] study))
    (ADVP (RB:[2119..2127] strongly))
    (VP (VBZ:[2128..2136] suggests)
      (SBAR (IN:[2137..2141] that)
        (S
          (NP-SBJ
            (NP (NN:[2142..2146] drug) (NNS:[2147..2159] interactions))
            (VP (VBN:[2160..2168] elicited)
              (NP (-NONE-:[2168..2168] *))
              (PP (IN:[2169..2171] by)
                (NP-LGS (NN:[2172..2184] thioridazine)))))
          (VP (VBP:[2185..2188] are)
            (ADVP (RBS:[2189..2193] most) (RB:[2195..2201] likely))
            (NP-PRD
              (NP (DT:[2202..2203] a) (NN:[2204..2215] consequence))
              (PP (IN:[2216..2218] of)
                (NP
                  (NP (JJ:[2219..2229] inhibitory)
                      (NNS:[2230..2242] interactions))
                  (PP (IN:[2243..2247] with)
                    (NP (NN:[2248..2253] P-450) (NNS:[2254..2261] enzymes))))))))))
    (.:[2261..2262] .)))

;section 17 Span:2266..2310
;PMID: 2604739 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2266..2270] PMID) (::[2270..2271] :) (CD:[2272..2279] 2604739)
        (NN:[2280..2281] -LSB-) (NNP:[2281..2287] PubMed) (::[2288..2289] -)
        (NN:[2290..2297] indexed) (IN:[2298..2301] for)
        (NNP:[2302..2310] MEDLINE-RSB-)))
